1 / 37

Section C Madulara Magno Magsino Malig Mallari Mamba Manguba Mangubat Mansukhani Manzana

Severe Pre- Eclampsia. Section C Madulara Magno Magsino Malig Mallari Mamba Manguba Mangubat Mansukhani Manzana. Pre-eclampsia. the presence of hypertension and proteinuria occurring after 20 th week of gestation. Indications of Severe Pre-eclampsia.

naasir
Download Presentation

Section C Madulara Magno Magsino Malig Mallari Mamba Manguba Mangubat Mansukhani Manzana

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Severe Pre-Eclampsia Section C Madulara Magno Magsino Malig Mallari Mamba Manguba Mangubat Mansukhani Manzana

  2. Pre-eclampsia • the presence of hypertension and proteinuria occurring after 20th week of gestation

  3. Indications of Severe Pre-eclampsia

  4. Incidence – Philippine Setting • According to Dept. of Health, Maternal Mortality Rate (MMR) • 162 out of 10,000 live births (Family Planning Survey 2006) • Maternal deaths account for 14% of deaths among women • For the past 5 years, all of the causes of maternal deaths exhibited an upward trend. • Pre-Eclampsia showed an increasing trend of 6.89%, 20%, 40%, and 100% • 10 women die everyday in the Philippines due to pregnancy and childbirth-related causes, such as pre-eclampsia

  5. Severe Pre-eclampsia • BP 160/110 mmHg • Proteinuria: • at least 4 g/day or persistent > +2 on dipstick • Oliguria: • <400 cc/day • Signifying decreased renal blood flow and diminished glomerular filtration rate • Severe headache and visual disturbance • Pulmonary edema or cyanosis • Due to hemodynamic changes (inc. afterload)

  6. Severe Pre-eclampsia • Abdominal pain (epigastric or RUQ location) • distention of glisson’s capsule of the liver due to heptocellular edema and/or necrosis • Hemolysis • inc. serum LDH, hemoglobinuria, hyperbilirubinemi, presence of schistocytes • Elevated liver enzymes • Due to hepatocellular necorsis • Thrombocytopenia • Due to microangiopathic hemolysis induced by spasm

  7. Signs to identify include: • Cardiovascular system: hypertension, vasoconstriction leading to cool peripheries, peripheral oedema • Respiratory system: pulmonary edema, facial and laryngeal edema, acute respiratory distress syndrome (ARDS) • Renal system:proteinuria, oliguria, acute renal failure • Central nervous system: hyperreflexia, clonus, cerebral haemorrhage, convulsions (eclampsia), papilloedema, coma • Others: HELLP (Haemolysis, Elevated Liver Enzymes and Low Platelets), thrombocytopenia, DIC (disseminated intravascular coagulopathy) • Fetal signs include: CardioTocoGraphy (CTG) abnormalities, pre-term labour, and intrauterine growth retardation.

  8. Risk factors associated with pregnant women: • First pregnancy • Age under 20 or above 35 • High BP before pregnancy • Previous pre-eclamptic pregnancy • Short interpregnancy intervals • Family history • Obesity • DM, kidney disease, rheumatioud arthritis, lupus, or scleroderma • Low socio-economic status • Poor protein or low calcium in the diet

  9. Risk factors associated with the pregnant women’s husband: Risk factors associated with the fetus: Multifetal pregnancy Hydrops/triploidy Hydatidiform mole • First time father • Previously fathered a pre-eclamptic pregnancy

  10. Risk factors and their odds ratio for pre-eclampsia

  11. PE Findings • BP > 160/110 mmHg • Proteinuria 2.0g/24 hrs or > 2+ dipstick • Serum creatinine > 1.2 mg/dL unless previously elevated • Platelets < 100,000 mm3 • Microangiopathichemolysis: Elevated LDH

  12. PE Findings • Persistent headache, visual disturbance, epigastric pain • Increase serum transaminase • Obvious growth restriction • Pulmonary edema: increase permeability in maternal circulation

  13. Laboratory Tests • Hematocrit • Increased hematocrit levels in pre-eclampsia • Proteinuria • More than 300 mg/24h or dipstick values of 1+ denotes poor prognosis • Serum uric acid • Correlate with the development and severity of pre-eclampsia, and increased perinatal mortality

  14. Ultrasound • Doppler velocimetry • Diastolic notch • Increased systolic/diastolic index (Stuart index) • Pulsatility index • Absence or reversed end diastolic blood flow

  15. TREATMENT

  16. TREATMENT • 3 cardinal principles: A. control of convulsions B. Control of hypertension C. Delivery at optimum time and mode

  17. CONTROL OF CONVULSION • D.O.C : MAGNESIUM SULFATE • Versus Diazepam: reduced recurrence of convulsions; reduced maternal mortality; fewer APGAR scores <7 at 5 mins. • Versus Phenytoin: reduced recurrence of convulsions; fewer admissions to NICU and fewer babies who died • Versus Lytic cocktail: reduced recurrence of convulsions; less respiratory depression; less maternal deaths

  18. CONTROL OF CONVULSION • Thus, Magnesium Sulfate: - reduces risk of eclampsia - Reduces risk of maternal death • SIDE EFFECTS: - neutropenia - nosocomial infections in infants - Lower fetal biophysical profile by decreasing breathing - Increased incidence of nonreactive NST - Decreased variability of FHR - Disturbed fetal and maternal calcium homeostasis and bone density

  19. CONTROL OF CONVULSION • DOSE: • Loading dose – 4 gm IV slowly over 5 mins Maintenance dose -1-2 Gms per hour IV drip • Loading dose – 4 Gm IV slowly over 5 mins and 10 gm IV (5gm on each buttock) Maintenance – 5 Gms IM every 6 hours

  20. CONTROL OF CONVULSION • Monitoring: • Presence of DTRs • RR of >12 per minute • Urine output at least 100cc every 4 hours • Serum magnesium

  21. CONTROL OF HYPERTENSION • Use of anti-hypertensives for BP at least 160/110 mmHg – to prevent maternal CVA-Hemorrhage • D.O.C: HYDRALAZINE • Initial dose: 5 mg IV bolus followed by 5 mg incremental increases half-hourly if diastolic BP does not improve up to a total dose of 20mg • Beta blockers (labetalol) • Lowers systolic and diastolic BP • Prevent more severe forms of PIH • Prevent ventricular arrythmia, tachycardia and pulmonary edema • ADVERSE EFFECTS on fetal growth and fetal hemodynamics

  22. CONTROL OF HYPERTENSION • Calcium-channel blocker • Nifedipine • Reduce maternal BP, proteinuria and improve renal function • Given sublingually: prevent erythrocyte aggregation • Nicardipine: • More selective on peripheral vasculature • Less inotropic effect: tachycardia, flushing and hot flushes • Lower rate of placental transport with limited exposure of fetal tissues

  23. CONTROL OF HYPERTENSION • Sodium nitroprusside • For signs of severe hypertensive encephalopathy • ACE inhibitors • Not recommended due to fetal side effects (defective skull ossification, oligohydramnios, neonatal anuria) • Diuretics • Not used unless with evidence of pulmonary edema or congestion

  24. OPTIMUM TIME AND MODE OF DELIVERY • 5 Factors: • Age of gestation • Severity of disease • Fetal status • Maternal condition • Nursery capabilities

  25. OPTIMUM TIME AND MODE OF DELIVERY • General guidelines: • Hospitalize all patients once signs or symptoms of pre-eclampsia are evident • Immediate delivery done for: • All cases of eclampsia regardless of age of gestation • Severe pre-eclamptics at least 34 wks in presence of mature fetal lung and adequate nursery facilities; - Complications may mandate delivery <34 wks AOG thus, steroids are advised

  26. OPTIMUM TIME AND MODE OF DELIVERY c. Severe maternal disease - uncontrollable hypertension of 160/110 - oliguria <400 hours - thrombocytopenia <100,000/cu SGPT - pulmonary edema - impending eclampsia d. Fetal compromise - abnormal fetal movement counting - CTGs - BPS - ARED patterns on Doppler velocimetry

  27. OPTIMUM TIME AND MODE OF DELIVERY 3. Presence of clinical disease at <34 wks AOG - conservative management: - evaluation of maternal and fetal status - therapy with anticonvulsant, antihypertensive, low dose aspirin and high dose calcium 4. Labor and Delivery options: - cervical ripening with oxytocin or prostaglandins - amniotomy - vaginal or cesarean delivery

  28. OPTIMUM TIME AND MODE OF DELIVERY • Similar treatment protocol with Parkland hospital but we are more liberal on use of CS especially if: • Intact fetus is growth restricted • Bishop’s score <5 • Fetal BPS score <6/10 • CTG tracing shows persistent late or severe variable decelerations

  29. PREVENTION

  30. BMI and Diet • BMI > 30 increases the risk of pre-eclampsia • Obesity  augmented placental production of leptin, adinopectin or triglycerides and inflammation •  Drinking water • avoid salty foods, junk foods and foods that are fried • Avoid alcohol and caffeinated beverages • exercise

  31. Low dose aspirin • Doses are kept at 60-80 mg/day • Selective thromboxane (TXL-A2) suppression with resultant dominance of endothelial prostacyclin (PGI) • Monitoring of platelet counts, coagulation profiles, fetal ductusarteriosus, urine production/amniotic fluid. • Indications: • High-risk • Started during the 2nd trimester to prevent fetal malformations • Contraindications: • Aspirin allergy or hypersensitivity (acid peptic disease or coagulopathy

  32. High Dose Calcium • oral intake of calcium (2g/day) • Reduction in IUGR and BP levels • Exerts a negative feedback effect on parathyroid hormone decrease calciumsmooth muscle relaxation and diminished responsiveness to pressor stimuli

  33. Associated with higher levels of calcium excretion which is coupled with an ion exchange with magnesium sulfate • Increased levels of magnesium sulfate  smooth muscle relaxation in blood vessels  control of hypertension

  34. Thank You!

More Related